By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

The Medicines Company 

8 Sylvan Way

Parsippany  New Jersey  07054  U.S.A.
Phone: 973-290-6000 Fax: 973-656-9898


SEARCH JOBS




Collaborations

UCB, Inc.  Contract manufacturing of Bivalirudin peptide active ingredient





Company News
The Medicines Company (MDCO) To Webcast Infectious Disease Care Investor & Analyst Day On September 24 9/24/2014 8:59:52 AM
The Medicines Company (MDCO) To Review ORBACTIV™ (Oritavancin) Launch Readiness On Tuesday, September 16, 2014 9/12/2014 10:52:41 AM
The Medicines Company (MDCO) To Present New Data From Its Infectious Disease Portfolio At The 54th Interscience Conference On Antimicrobial Agents And Chemotherapy (ICAAC) 8/28/2014 1:03:14 PM
FDA Approves The Medicines Company (MDCO)'s Acute Skin Infection Drug Orbactiv 8/6/2014 5:30:57 PM
The Medicines Company (MDCO) To Host Infectious Disease Care Investor And Analyst Meeting On September 24, 2014 8/4/2014 10:07:50 AM
The Medicines Company (MDCO) Reports Second Quarter And First Half 2014 Results 7/23/2014 1:12:19 PM
The Medicines Company (MDCO) To Announce Second Quarter And First Half 2014 Financial Results On Wednesday, July 23, 2014 7/9/2014 10:58:02 AM
Controversial Trial Discovers No Benefit For Expensive The Medicines Company (MDCO) Drug 7/8/2014 6:30:00 AM
The Medicines Company (MDCO) Receives Market Authorization Renewal For Angiox® (Bivalirudin) From The European Medicines Agency And The European Commission 7/7/2014 10:13:38 AM
The Medicines Company (MDCO) Release: ORBACTIV™ (Oritavancin) Phase 3 Trial Results Published In The New England Journal of Medicine 6/5/2014 9:18:26 AM
12345678910...
//-->